Overall, our findings offer promising combinatorial treatments targeting NR2E3 in cervical cancer and retinoblastoma cells, highlighting NR2E3 as a novel molecular vulnerability in solid tumors. This evidence concerns the gene NR2E3 and cervical cancer.